Reactions to peanut at first introduction in infancy are associated with age ≥8 months and severity of eczema

Dirk H J Verhoeven1,2, Irene C E M Herpertz3, Jeroen Hol4

  • 1Department of Pediatrics, Reinier de Graaf Hospital, Delft, The Netherlands.

Insights

Early introduction of peanut before 8 months may prevent allergic reactions in infants, especially those with eczema. Introducing peanut by 7 months is recommended for infants with severe eczema to minimize risks.

Area of Science:

  • Pediatric Allergology
  • Immunology
  • Clinical Nutrition

Background:

  • Previous research indicates early peanut introduction prevents peanut allergy.
  • Optimal timing is unclear due to prior exclusion of sensitized infants.

Purpose of the Study:

  • Determine the optimal timing for peanut introduction to prevent allergic reactions.
  • Investigate risk factors for reactions during early peanut introduction.

Main Methods:

  • The PeanutNL study involved 707 infants across 6 Dutch pediatric centers.
  • Infants underwent skin prick tests and oral peanut challenges around 6 months of age.
  • Multivariate analysis identified age and eczema severity as risk factors.

Main Results:

  • 23% of infants were sensitized to peanut; 9.5% had positive oral challenges.
  • Introducing peanut at ≥8 months increased reaction risk in infants with moderate/severe eczema.
  • Family history of peanut allergy and egg reactions were not independent risk factors.

Conclusions:

  • Peanut introduction before 8 months is suggested to reduce reaction risk in infants with moderate to severe eczema.
  • Clinical introduction by 7 months is advised for infants with severe eczema due to highest reaction risk.
Abstract

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
27.8K
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
898
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.7K
Cross-reactivity00:42

Cross-reactivity

Overview
31.3K
Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
799
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357